Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference
Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3rd at 4:30 p.m. ET.
The company currently markets two key products: HEPLISAV-B, an approved hepatitis B vaccine for adults in the US, EU, and UK, and CpG 1018 adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.
Dynavax Technologies (Nasdaq: DVAX), una societ脿 biofarmaceutica in fase commerciale focalizzata sullo sviluppo di vaccini innovativi, parteciper脿 a una fireside chat al Wells Fargo Healthcare Conference 2025 il 3 settembre alle 16:30 ET.
La societ脿 commercializza attualmente due prodotti principali: HEPLISAV-B, un vaccino approvato contro l'epatite B per gli adulti negli Stati Uniti, nell'UE e nel Regno Unito, e il CpG 1018 adjuvant, impiegato in HEPLISAV-B e in diversi vaccini contro il COVID-19.
Dynavax Technologies (Nasdaq: DVAX), una compa帽铆a biofarmac茅utica en fase comercial centrada en el desarrollo de vacunas innovadoras, participar谩 en una charla informal en el Wells Fargo Healthcare Conference 2025 el 3 de septiembre a las 4:30 p.m. ET.
La empresa comercializa actualmente dos productos clave: HEPLISAV-B, una vacuna contra la hepatitis B aprobada para adultos en EE. UU., la UE y el Reino Unido, y el adyuvante CpG 1018, utilizado en HEPLISAV-B y en diversas vacunas contra la COVID-19.
Dynavax Technologies (Nasdaq: DVAX), 順侅嫚鞝侅澑 氚膘嫚 臧滊皽鞐� 欤茧牓頃橂姅 靸侅梾 雼硠鞚� 氚旍澊鞓れ牅鞎届偓搿滌劀, 2025 Wells Fargo Healthcare Conference鞐愳劀 9鞗� 3鞚� 鞓ろ泟 4鞁� 30攵�(ET)鞐� 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃╇媹雼�.
須岇偓電� 順勳灛 霊� 臧�歆� 欤检殧 鞝滍拡鞚� 韺愲Г頃橁碃 鞛堨姷雼堧嫟: HEPLISAV-B電� 氙戈淡, EU 氚� 鞓侁淡鞐愳劀 靹膘澑鞖╈溂搿� 鞀轨澑霅� B順曣皠鞐� 氚膘嫚鞚措┌, CpG 1018 氤挫“鞝�電� HEPLISAV-B鞕� 鞐煬 COVID-19 氚膘嫚鞐� 靷毄霅╇媹雼�.
Dynavax Technologies (Nasdaq: DVAX), une soci茅t茅 biopharmaceutique en phase commerciale ax茅e sur le d茅veloppement de vaccins innovants, participera 脿 une conversation informelle lors de la Wells Fargo Healthcare Conference 2025 le 3 septembre 脿 16h30 (ET).
L'entreprise commercialise actuellement deux produits cl茅s : HEPLISAV-B, un vaccin contre l'h茅patite B approuv茅 pour les adultes aux 脡tats-Unis, dans l'UE et au Royaume-Uni, et l'adjuvant CpG 1018, utilis茅 dans HEPLISAV-B et plusieurs vaccins contre la COVID-19.
Dynavax Technologies (Nasdaq: DVAX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase mit Schwerpunkt auf der Entwicklung innovativer Impfstoffe, wird an einem Fireside-Chat auf der Wells Fargo Healthcare Conference 2025 am 3. September um 16:30 Uhr ET teilnehmen.
Das Unternehmen vertreibt derzeit zwei Hauptprodukte: HEPLISAV-B, einen f眉r Erwachsene zugelassenen Hepatitis-B-Impfstoff in den USA, der EU und dem Vereinigten K枚nigreich, sowie den CpG 1018 Adjuvans, der in HEPLISAV-B und in verschiedenen COVID-19-Impfstoffen verwendet wird.
- None.
- None.
The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at聽.
础产辞耻迟听顿测苍补惫补虫
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B庐 vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the
For Investors/Media:
Paul Cox
[email protected]
510-665-0499
狈颈肠辞濒别听础谤苍诲迟
[email protected]
510-665-7264
View original content to download multimedia:
SOURCE Dynavax Technologies
FAQ
When is Dynavax (DVAX) presenting at the Wells Fargo Healthcare Conference 2025?
How can investors access Dynavax's Wells Fargo conference presentation?
What are Dynavax's (DVAX) main commercial products?
Where is HEPLISAV-B vaccine approved for use?
